Peptonic receives approximately SEK 49.9 thousand through warrants of series TO5

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW.

PEPTONIC medical AB ("Peptonic" or the "Company") today announces the outcome of the exercise of warrants of series TO5 (”TO5”). In total, 3,839,942 TO5 were exercised, corresponding to approximately 0.18 percent of the total number of outstanding TO5, for subscription of 3,839,942 shares at a subscription price of SEK 0.013 per share. Through the exercise of TO5, Peptonic will receive approximately SEK 49.9 thousand before issuing costs.

The exercise period for exercise of TO5 took place from and including November 6, 2024, up to and including November 20, 2024. The subscription price per share for exercising TO5 was set to SEK 0.013.

In total, 3,839,942 TO5 were exercised for subscription of, 3,839,942 shares, meaning that approximately 0.18 percent of all outstanding TO5 were exercised.

Exercised TO5 have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to shares within approximately three (3) weeks.

Shares, share capital and dilution

Through the exercise of TO5, the number of shares in Peptonic increases by 3,839,942 shares, from 5,755,463,072 shares to a total of 5,759,303,014 shares. The share capital will increase by approximately SEK 26,879.59 from approximately SEK 40,288,242.09 to approximately SEK 40,315,121.68.

For existing shareholders who did not exercise any TO5, the dilution amounts to approximately 0.07 percent of the number of shares and votes in the Company.

Advisers

Mangold Fondkommission AB is financial adviser and Eversheds Sutherland Advokatbyrå AB is legal adviser to Peptonic in connection with the utilization of TO5.

For further information, please contact:

Anna Linton, CEO Peptonic Medical AB
Email: [email protected]
Phone:  +46 70-244 92 07

About PEPTONIC medical AB

Peptonic Medical AB (publ) is a cutting-edge Swedish biomedical company, dedicated in the development and distribution of clinically proven self-care treatments and self-diagnostic tests in intimate women's health. The portfolio is sold under the brands Vagivital and Vernivia. The company's vision is to revolutionize intimate health by empowering women to diagnose, treat, and prevent intimate medical conditions independently and effectively. Intimate health shall be natural, safe, and easy for women to manage on their own.

Central to Peptonic's growth strategy is the geographical expansion of VagiVital and Vernivia through local partners. Peptonic Medical also intends to continuously broaden its product portfolio through acquisitions and the development of innovative and competitive products in-house. The company's mousse-based drug delivery technology, Venerol, and the gel base in VagiVital create favorable conditions for expanding the portfolio.

The company is headquartered in Stockholm, Sweden, and has subsidiaries Common Sense Marketing Inc in the USA and Peptonic Medical Ltd in Israel. Peptonic Medical was founded in 2009, and the company's shares have been listed on the Spotlight Stock Market since 2014.

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Peptonic in any jurisdiction, neither from Peptonic nor anyone else.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, South Africa, the United States, Belarus, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.